On the other hand, a genetic analysis of the large EUCLID trial (n = 13,885) that recruited patients with symptomatic PAD reported no difference in cardiovascular outcomes between patient subgroups with different CYP2C19 genotypes [120]. Here, CYP2C19 is linked to peripheral arterial disease.